GLP-1
A tipster told BioSpace that the layoffs were initially announced by Intarcia CEO Kurt Graves on Jan. 31.
The trial was conducted at Rigshospitalet, University of Copenhagen, Denmark, one of the world’s leading centers for the treatment of SBS and top-line results were reported in June 2017
3SBio reported the CFDA formally approved Bydureon, its once-weekly Glucagon-like peptide-1 receptor agonist for type 2 diabetes treatment.
Investors are salivating at the possibility of a hot merger-and-acquisition market in 2018.
reMYND’s pre-clinical diabetes therapy ReS39 will get a significant boost after the company entered a licensing agreement with noted European diabetes company Novo Nordisk.
There are hundreds, even thousands of biotech and pharmaceutical companies.
As 2017 comes to a close, 40 drugs have been approved so far, with the record being in 2015, when 46 drugs were approved.
The company’s demise was explained in a blog post by Atlas Venture partner Bruce Booth.
After falling short of analysts’ expectations in its latest quarter, Novo Nordisk is restructuring its commercial operations as it looks to fend off challenges to its products.
The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
PRESS RELEASES